


GlucanosomTM

Supports Natural Defences



Reduced Sensitivity against Common Cold: Summary of Study Results

ABAC R&D Ltd.

Switzerland

Study Design and Status

Study design

Double-blind, randomized, placebo-controlled, multi-centered nutritional study:

- Duration: 26 weeks
- Test persons: 100
- Prophylactic daily dosage: 2x 0.45 g
- Therapeutic daily dosage: 2x 0.9 g

Status

Since Glucanosom™ is in the process of health claim approval (EU), only a study summary can be published.

Results


The direct perception of the test persons with regard to the efficiency of Glucanosom™ against common cold in the cold season was recorded:

- ✓ Proved prophylactic effect in the cold season.
- ✓ Proved reduction of cold symptoms.
- ✓ Faster recovery from common cold proved.
- ✓ Explicitly better rated compared to placebo.
- ✓ Good compatibility – no known side effects.

Prophylactic Effect of Glucanosom™


Reduced number of periods of common cold

During the first three months (December to March) of the application Glucanosom™ resulted in a significant reduction of the appearance of common cold.



Lower intensity of symptoms on the first day


Independent on the type of symptom application of Glucanosom™ had a positive effect. Different symptoms were markedly less expressed.



Therapeutic Effect of Glucanosom™

Explicitly milder symptoms

Glucanosom™ is effective from the first day on when cold symptoms show up and leads to a milder progression of the cold until it disappears.



Convincing perception of effectivity

The effectivity of Glucanosom™ during a defined period of common cold is assessed as good to very good by more than 75% of the test persons.

